A PROSPECTIVE-STUDY OF PLASMA-HORMONE LEVELS, NONHORMONAL FACTORS, AND DEVELOPMENT OF BENIGN PROSTATIC HYPERPLASIA

被引:110
作者
GANN, PH
HENNEKENS, CH
LONGCOPE, C
VERHOEKOFTEDAHL, W
GRODSTEIN, F
STAMPFER, MJ
机构
[1] HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV PREVENT MED,BOSTON,MA 02115
[2] HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CHANNING LAB,BOSTON,MA 02115
[3] HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115
[4] HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA 02115
[5] UNIV MASSACHUSETTS,MED CTR,DEPT OBSTET & GYNECOL,WORCESTER,MA
[6] UNIV MASSACHUSETTS,MED CTR,DEPT MED,WORCESTER,MA
[7] BROWN UNIV,DIV BIOL & MED,PROVIDENCE,RI 02912
关键词
BENIGN PROSTATIC HYPERPLASIA; RISK FACTORS; BLOOD PRESSURE; STEROID HORMONES; ESTRADIOL;
D O I
10.1002/pros.2990260109
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We assessed the relation of plasma hormone levels and nonhormonal factors with subsequent occurrence of surgical treatment for benign prostatic hyperplasia (BPH) among participants in the Physicians' Health Study. Frozen plasma samples, collected at the study onset, were available for 320 men who developed surgically treated BPH up to 9 years later and for 320 age-matched controls. Plasma testosterone (T), dihydrotestosterone (DHT), androstenedione, estradiol (E2), and estrone (E1) were measured for each case-control pair. In unadjusted analyses, none of the hormones or hormone ratios were associated with BPH; for example, for T and E2 the odds ratios (OR) comparing the highest quintile (Q5) with the lowest (Q1) were 0.74 (95% CI = 0.42, 1.30) and 1.07 (95% CI = 0.51, 2.22), respectively. However, in multivariate analyses controlling diastolic blood pressure, exercise, alcohol, E1, and DHT:T ratio, we observed a strong trend for increasing risk across quintiles for E2 (Q5 vs. Q1 OR = 3.56, P trend = 0.009), and a weak inverse trend for E1 (05 vs Q1 OR = 0.51, P trend = 0.07). The excess risk associated with E2 was confined to men with relatively low androgen levels. Three nonhormonal factors previously suspected as risk factors were independently associated with surgical BPH in these data. The OR for a 1-mm Hg difference in diastolic blood pressure was 1.04 (95% CI = 1.01, 1.07). Alcohol use and infrequent exercise were inversely associated with risk of BPH surgery; however, risk estimates were not consistent across categories of exercise and alcohol frequency. Our results indicate that normal variation in circulating androgen levels does not influence development of BPH, but that variation in estrogen levels might be important. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:40 / 49
页数:10
相关论文
共 31 条
[1]  
Guess HA, Benign prostatic hyperplasia: Antecedents and natural history, Epidemiol Rev, 14, pp. 131-153, (1992)
[2]  
Wilson JD, The pathogenesis of benign prostatic hyperplasia, Am J Med, 68, pp. 745-756, (1980)
[3]  
Thigpen AE, Davis DL, Gautier T, Et al., Brief report: the molecular basis of steroid 5α‐reductase deficiency in a large Dominican kindred, N Engl J Med, 327, pp. 1216-1219, (1992)
[4]  
Gormley GJ, Stoner E, Bruskewitz RC, Et al., The effect of finasteride in men with benign prostatic hyperplasia, N Engl J Med, 327, pp. 1185-1191, (1992)
[5]  
Walsh PC, The role of estrogen/androgen synergism in the pathogenesis of benign prostatic hyperplasia, J Urol, 139, (1988)
[6]  
Hulka BS, Hammond JE, DiFerdinando G, Serum hormone levels among patients with prostatic carcinoma or benign prostatic hyperplasia and clinic controls, Prostate, 11, pp. 171-182, (1987)
[7]  
Drafta D, Proca E, Zamfir V, Et al., Plasma steroids in benign prostatic hypertrophy and carcinoma of the prostate, J Steroid Biochem, 17, pp. 689-693, (1982)
[8]  
Bartsch W, Becker H, Pinkenburg FA, Et al., Hormone blood levels and their interrelationships in normal men and men with benign prostatic hyperplasia (BPH), Acta Endocrinol, 90, pp. 727-736, (1979)
[9]  
Brochu M, Belanger A, Comparative study of plasma steroid and steroid glucuronide levels in normal men and men with benign prostatic hyperplasia, Prostate, 11, pp. 33-1140, (1987)
[10]  
Hammond GL, Kontturi M, Vihko P, Vihko R, Serum steroids in normal males and patients with prostatic diseases, Clin Endocrinol, 9, pp. 113-121, (1978)